Immunoglobulin inhibitors - Pipeline Insight, 2024

This “Immunoglobulin inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Immunoglobulin inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Immunoglobulin inhibitors Understanding

Immunoglobulin inhibitors: Overview

The interactions between immunoglobulin E (IgE) and its two receptors, Fce RI and CD23 (Fce RII), play pivotal roles in allergic disease. FceRI is principally expressed on the surface of mast cells and basophils. Allergen mediated cross-linking of FceRI-bound IgE on the surface of these IgE-sensitized cells triggers degranulation and release of inflammatory mediators. CD23 is expressed in membrane-bound (mCD23) and soluble forms, the latter existing as monomeric or trimeric fragments. Inhibiting the interaction between IgE and FceRI, but not CD23, is thus a potentially promising therapeutic approach in the treatment ofallergicdisease.

The importance of immunoglobulin E (IgE) in atopic disorders such as asthma, allergic rhinitis, food allergies, and atopic dermatitis is well established. Elevation of total serum IgE is typically found in many atopic patients, and in predisposed individuals, allergen-specific IgE is produced. The availability of humanized monoclonal antibodies against IgE has provided a new therapeutic option and tool to explore the role IgE in allergic diseases and the effects of inhibiting IgE itself. Clinically, anti-IgE therapy has already been proven to be useful in the treatment of asthma and allergic rhinitis.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Immunoglobulin inhibitors R&D. The therapies under development are focused on novel approaches for Immunoglobulin inhibitors.

Immunoglobulin inhibitors Emerging Drugs Chapters

This segment of the Immunoglobulin inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immunoglobulin inhibitors Emerging Drugs

Ligelizumab: Novartis Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/Fce RI pathway, a key driver of the inflammatory process in Chronic Spontaneous Urticaria (CSU). U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response toH1-antihistaminetreatment.

It is currently in Phase III stage of development and is being developed by Novartis.

Immunoglobulin inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Immunoglobulin inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Immunoglobulin inhibitors

There are approx. 5+ key companies which are developing the Immunoglobulin inhibitors. The companies which have their Immunoglobulin inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Immunoglobulin inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Immunoglobulin inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immunoglobulin inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immunoglobulin inhibitors drugs.

Immunoglobulin inhibitors Report Insights

• Immunoglobulin inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Immunoglobulin inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Immunoglobulin inhibitors drugs?
• How many Immunoglobulin inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Immunoglobulin inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immunoglobulin inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Immunoglobulin inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Yuhan
• Hansa Biopharma
• Epsilogen

Key Products

• Ligelizumab
• YH-35324
• Imlifidase
• MOv18 IgE

This product will be delivered within 2 business days.